48.70
+3.84%
Close of 9 Nov 2026, in TWD
Search any instrument
Reference data, closing prices and charts across 45,000 companies, plus crypto, commodities and currencies.
About Medigen Vaccine Biologics
Its shares trade on Taipei Exchange under the ticker 6547.TWO. It has been listed since 6 August 2015. In the fiscal year to 31 December 2025, it reported revenue of TWD 613.2m and a net loss of TWD 281.7m. At that date it held total assets of TWD 3.93bn and shareholders' equity of TWD 3.48bn.
Medigen Vaccine Biologics Corp. engages in the research, development, and wholesale of vaccine and biopharmaceutical, and wholesale and retail of medical devices. The company is headquartered in Zhubei, Hsinchu. The company went IPO on 2015-08-06. The firm is engaged in the development of cutting edge technologies for cell-based human vaccines production. For vaccine development, the Company has established the manufacturing process for H1N1 and H5N1. Further, it also conducts clinical trials to confirm safety and efficacy of produced vaccines. In addition, the Company is also engaged in biological agents business.
Figures and description from our data supplier, not checked against the company's own report.
Company facts
- Sector
- Health Care
- Industry
- Biotechnology
- Listed since
- 6 Aug 2015
- Website
- medigenvac.com ↗
Leadership
Pay as last reported
- Mr. Ming-Cheng ChangChairman of the Board, since 2015TWD 2.8m
- Mr. Ssu-Hsien LiGeneral ManagerTWD 7.8m
- Mr. Sheng-Ying KeDeputy General Manager-Medical Affairs & Clinical Division
- Ms. Yu-Ping YangDeputy General Manager-Administration Division, Head of AccountingTWD 5.3m
- Mr. Wei-Cheng LienHead of FactoryTWD 4.8m
- Ms. Chin-Yen ChenDirectorTWD 214,000
- Mr. Tsan-Jian ChenDirector, since 2016TWD 2.4m
- Mr. Chia-Hsiu LinDirectorTWD 553,000
- Mr. Yao-Chi LiIndependent DirectorTWD 680,000
- Mr. Peng-Fei SuIndependent DirectorTWD 391,000
- Mr. Ming-Yi WuIndependent DirectorTWD 670,000
Environmental, social and governance
Scores out of 100, from our data supplier
- Overall
- 0
- Environment
- 0
- Social
- 0
- Governance
- 0
SWOT analysis
AI-generated by our data supplier. Not written or checked by our editors.
Strengths
- Medigen Vaccine Biologics Corp. develops H1N1 and H5N1 vaccine manufacturing processes in Zhubei, Taiwan.
- The company conducts clinical trials for vaccine safety and efficacy in the Health Care sector.
- Medigen focuses on cell-based human vaccines production using cutting edge technologies.
Weaknesses
- The company's business is limited to vaccine and biopharmaceutical wholesale in Taiwan.
- Medigen's operations are confined to Zhubei, Hsinchu, restricting market reach.
- The firm has no reported expansion plans beyond current vaccine development.
Opportunities
- The global demand for H1N1 and H5N1 vaccines presents growth opportunities.
- Medigen can leverage its biopharmaceutical expertise in the Health Care industry.
- Expanding clinical trials could open new markets in the Biotechnology sector.
Threats
- Competition from other vaccine manufacturers in the Health Care sector poses a threat.
- Regulatory changes in Taiwan's Biotechnology industry could impact operations.
- The company faces potential supply chain disruptions in vaccine production.
Sources and methodology
- Data on this tab
- Our data supplier
- Chart on the Overview
- TradingView
Nothing here is investment advice. Prices can be delayed or wrong, so check with the exchange before relying on them. Data for this page. How we cover markets.